Does Medicare Advantage Cover Wegovy?

The Federal Rule That Blocks Most Wegovy Coverage

Federal law is the starting point. Since 1990, Social Security Act Section 1860D-2(e)(2)(A) has explicitly excluded drugs used for "weight loss" from Medicare Part D coverage. The CMS Medicare Prescription Drug Benefit Manual, Chapter 6 codifies this exclusion. Every Medicare Advantage plan that includes Part D drug coverage inherits this prohibition unless an exception applies.

Semaglutide 2.4 mg (Wegovy) launched in June 2021 with an FDA-approved indication for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity. STEP-1 (N=1,961) demonstrated 14.9% mean body-weight reduction at 68 weeks versus 2.4% with placebo (P<0.001), establishing the clinical rationale for the drug. [1] Because that indication is weight management, standard Part D plans could not cover it.

The Treat and Reduce Obesity Act has been reintroduced in Congress repeatedly to lift this exclusion, but as of mid-2025 it has not passed into law. Current legislative status is tracked by the Obesity Society. Until Congress acts, the exclusion stands for the weight-loss indication.

The March 2024 Cardiovascular Indication Changed the Equation

Wegovy's coverage picture shifted materially on March 8, 2024, when the FDA approved an expanded label for semaglutide 2.4 mg to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease (CVD) and either obesity or overweight. The full prescribing information is available on the FDA website. [2]

This approval rested on the SELECT trial (N=17,604), which showed a 20% reduction in the composite MACE endpoint (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) over a median follow-up of 40 months, compared with placebo (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001). The SELECT trial results were published in the New England Journal of Medicine. [3] The absolute risk reduction translated to 1.5 fewer MACE events per 100 patients treated over approximately 3.3 years.

CMS issued guidance confirming that Part D plans may cover Wegovy when prescribed for this cardiovascular indication because the drug is no longer being used solely for weight loss in those patients. The cardiovascular indication is the functional key that unlocks Part D formulary access, but "may cover" is not the same as "must cover." Each carrier decides independently whether to add Wegovy to its formulary and under what cost-sharing structure.

How Medicare Advantage Formularies Actually Work for Wegovy

Medicare Advantage plans submit their formularies to CMS annually. A plan that includes Wegovy for the CV indication typically places it on Specialty Tier (Tier 5), where coinsurance rather than a flat copay applies. CMS publishes formulary guidance in the Medicare Prescription Drug Benefit Manual. [4] At list price of approximately $1,349 per month, a 25% to 33% Tier 5 coinsurance means an out-of-pocket cost of roughly $337 to $445 per month during the coverage gap phase, even after the Inflation Reduction Act's $2,000 annual out-of-pocket cap takes effect in 2025.

The FDA drug database confirms semaglutide 2.4 mg's approved indications and label revisions. [5] Before calling your plan's member services line, pull the current plan formulary from Medicare Plan Finder at medicare.gov, enter the drug name "semaglutide," and filter by your plan. If semaglutide 2.4 mg does not appear, it is not on that formulary for this plan year.

Not all Medicare Advantage carriers have added Wegovy even for the CV indication. Coverage varies by carrier, by region, and by plan year. A plan that denied coverage in 2024 may have added it for 2025, and vice versa. Checking the formulary at each annual enrollment period (October 15 through December 7) is the only reliable approach.

Prior Authorization Criteria: What Plans Typically Require

Plans that do cover Wegovy almost universally require prior authorization (PA). PA criteria are carrier-specific, but common requirements drawn from published plan documents include the following:

Diagnosis documentation is the first gate. The prescriber must document established atherosclerotic cardiovascular disease (a prior myocardial infarction, stroke, or symptomatic peripheral arterial disease) combined with a BMI of 27 kg/m² or greater. Coverage for obesity-only without CVD remains generally unavailable under Part D.

Prescriber specialty requirements vary. Some plans require that the PA come from or be co-signed by a cardiologist or endocrinologist, though primary care prescribers can often submit the initial request with supporting cardiology records.

Contraindication documentation is also standard. Plans ask the prescriber to confirm the patient has no personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (the label's boxed warning). The full Wegovy prescribing information details contraindications. [2]

Concurrent medication review may be required. Because semaglutide can slow gastric emptying, some PA forms ask about concurrent use of oral medications with narrow therapeutic windows, including warfarin and certain oral contraceptives. Pharmacokinetic interaction data appear in the Wegovy prescribing information. [2]

Labs and vitals within a defined recency window (often 90 days) including HbA1c, lipid panel, and blood pressure readings round out most PA packets.

Step Therapy: What You May Need to Try First

Step therapy requires patients to try and fail one or more specified alternatives before a plan approves the target drug. For Wegovy under Medicare Advantage, step therapy protocols vary significantly.

For the cardiovascular indication, some plans require documented prior use of a statin and an ACE inhibitor or ARB as standard-of-care CV medications. The logic is that these agents should be in place regardless of semaglutide use. Other plans require a 90-day trial of a structured, supervised lifestyle program, typically defined as a program meeting the CMS-covered Intensive Behavioral Therapy (IBT) for obesity criteria, which covers 22 face-to-face visits in a 12-month period with a qualified primary care provider. CMS describes IBT coverage in the Medicare Learning Network. [6]

Some plans add an older weight-loss agent as a step, such as orlistat 120 mg three times daily. Orlistat is a Part D-covered drug for specific indications in some plans, though coverage is inconsistent. If your plan requires it, a 90-day orlistat trial with documented tolerability issues or inadequate response (typically defined as less than 5% body weight lost in 12 to 16 weeks) may satisfy the step.

Prescribers can challenge step therapy requirements that are clinically inappropriate. CMS rules codified at 42 CFR 423.560 give patients the right to request a step-therapy exception if the required drug is contraindicated, likely to cause an adverse reaction, or if the patient previously tried and failed the step drug. CMS step therapy regulations are available on the Electronic Code of Federal Regulations site. [7]

Appealing a Wegovy Denial from Medicare Advantage

Denials happen, but they are not final. Medicare Advantage follows a structured appeals process with defined timelines at each level.

Level 1: Plan Redetermination. Submit within 60 days of the denial notice. The plan must issue a decision within 7 calendar days for a standard appeal or 72 hours for an expedited appeal (used when the standard timeline could seriously jeopardize health). Attach updated clinical records, the published SELECT trial data, the FDA label change, and a letter of medical necessity from the treating cardiologist explicitly stating the cardiovascular (not weight-loss) indication.

Level 2: Qualified Independent Contractor (QIC) Review. If the plan upholds the denial, you have 60 days to escalate to a QIC. MAXIMUS Federal Services is the current CMS-contracted QIC for Medicare Advantage. Standard timeline is 7 days; expedited is 72 hours. MAXIMUS Federal Services contact and submission information is available at the CMS appeals resource page. [8]

Level 3: Office of Medicare Hearings and Appeals (OMHA). If the amount in controversy meets the threshold (currently $180 for 2025), you may request an Administrative Law Judge hearing within 60 days of the QIC decision.

Level 4: Medicare Appeals Council. A further escalation within the Department of Health and Human Services.

Level 5: Federal District Court. Available if the amount in controversy exceeds $1,870 (2025 threshold).

The single most effective lever in an appeal for the cardiovascular indication is framing. The denial is often issued under the Part D weight-loss drug exclusion. The appeal letter must clearly document that the prescriber is ordering Wegovy for MACE risk reduction under the March 2024 FDA-approved indication, not for weight management. The American Heart Association's 2023 obesity and cardiovascular disease scientific statement supports CV risk framing. [9] Attach that published statement as a supporting document.

A 2023 analysis by KFF (Kaiser Family Foundation) found that Medicare Advantage plans deny prior authorization requests at rates ranging from under 1% to over 25% depending on service type, and that roughly 80% of appealed denials that reach external review are overturned. KFF data on Medicare Advantage denials and appeals are published on the KFF website. [10] That overturn rate makes filing an appeal worth the effort.

The Manufacturer Savings Card Cannot Be Used with Medicare

This point is a hard stop. Novo Nordisk offers a savings card for commercially insured patients that can reduce Wegovy cost to as little as $25 per month. Medicare beneficiaries are explicitly excluded from using this card. Accepting it would violate the federal Anti-Kickback Statute and the CMS guidelines on cost-sharing subsidies. CMS guidance on manufacturer coupons and beneficiary inducements is available on the CMS compliance page. [11]

Alternative assistance programs for Medicare patients include:

Novo Nordisk's patient assistance program (PAP), which provides Wegovy at no cost to patients meeting income criteria (generally at or below 400% of the federal poverty level). Applications are submitted at novonordiskpaf.com, though income thresholds and formulary access change annually.

State pharmaceutical assistance programs (SPAPs) in about 24 states offer additional subsidy on top of Medicare Part D for qualifying low-income beneficiaries. CMS maintains a list of SPAPs on its Low Income Subsidy resource page. [12]

The Medicare Extra Help (Low Income Subsidy) program can reduce Specialty Tier cost-sharing substantially, potentially to a few dollars per month. Eligibility is based on income and assets; the 2025 individual income limit is approximately $22,590 per year. SSA Extra Help information is available at the Social Security Administration website. [13]

What Prescribers Should Document Before Submitting

Good documentation at the point of prescribing prevents most denials before they happen. A well-structured prior authorization packet includes the following:

The prescriber should record the ICD-10 code for the cardiovascular indication explicitly. The relevant code is Z87.39 (personal history of other endocrine, nutritional, and metabolic diseases) combined with codes for atherosclerotic heart disease (I25.10), prior MI (I25.2), prior stroke (I63.9 or Z86.73), or peripheral vascular disease (I73.9). Coding Wegovy only under E66 (obesity) is the most common reason a PA is routed to the weight-loss exclusion pathway.

Cardiology notes confirming the ASCVD diagnosis, dated within the past 12 months, should accompany the PA. A brief letter from the cardiologist stating "I am prescribing semaglutide 2.4 mg for cardiovascular risk reduction per the SELECT trial indication" carries significant weight with plan medical directors.

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease provides the framework for ASCVD risk documentation. [14] Citing guideline-concordant ASCVD risk scores in the PA letter aligns the request with established cardiology practice standards.

BMI and weight recorded in the chart within the past 90 days, HbA1c (to distinguish from a diabetes indication if applicable), blood pressure, and a current medication list complete most PA packets.

What Happens If Coverage Is Still Denied After All Appeals

Some patients will exhaust all appeal pathways and still face denial. Three realistic options remain:

First, check eligibility for the Novo Nordisk PAP described above. For patients at or below 400% of the federal poverty level, this can provide the drug at no cost while legislative or formulary changes work through the system.

Second, evaluate whether a non-Medicare insurance option is available. Patients who qualify for both Medicaid (dual eligibles) and Medicare should know that Medicaid drug coverage rules differ by state. Several state Medicaid programs do cover anti-obesity agents, though coverage is variable. Medicaid drug coverage policy is summarized on the Medicaid.gov website. [15]

Third, the prescriber and patient may want to discuss whether a GLP-1 receptor agonist with different coverage rules applies. Semaglutide 0.5 mg or 1 mg (Ozempic), approved for type 2 diabetes, is covered by Part D for patients who have a diabetes diagnosis. The 2.4 mg dose (Wegovy) and the 0.5/1 mg dose (Ozempic) are different FDA-approved products for different indications, and prescribing Ozempic off-label for weight loss in a Medicare patient would not meet Part D coverage requirements. FDA drug product information for semaglutide injection confirms the separate NDA numbers and indications. [5] Any prescribing decision should reflect the patient's actual clinical diagnosis.

What the Evidence Says About the Risk-Benefit Calculation

For patients with established CVD who cannot obtain coverage, the clinical stakes matter. SELECT (N=17,604) showed that over 40 months, semaglutide 2.4 mg reduced cardiovascular death, non-fatal MI, and non-fatal stroke by 20% versus placebo. [3] The number needed to treat (NNT) to prevent one MACE event was approximately 67 over the trial period. Published SELECT data are available in the New England Journal of Medicine. [3]

The American Heart Association's 2023 scientific statement on obesity and cardiovascular disease states: "Obesity is a chronic, complex, multifactorial disease that directly causes cardiovascular morbidity and mortality," and calls for treatment approaches that include pharmacotherapy as part of guideline-directed management. Full text is available at the AHA Journals site. [9]

The Endocrine Society's 2023 Clinical Practice Guideline on Pharmacological Management of Obesity recommends GLP-1 receptor agonists, including semaglutide, for patients with a BMI of 30 kg/m² or greater or a BMI of 27 kg/m² or greater with comorbidities, and specifies that treatment should be long-term to maintain weight loss achieved during active therapy. The Endocrine Society guideline is available at the Journal of Clinical Endocrinology and Metabolism. [16]

These two guideline sources, combined with the SELECT NNT of 67, give prescribers specific language and citation support for medical necessity letters.